normal dosage for tirzepatide chart: Zepbound and Mounjaro How Much Weight Will I

Individual differences in how bodies respond to the medication

Last month (May 2025), Novo announced that the US Food and Drug Administration (FDA) accepted its new drug application (NDA) submission for an investigational once-daily oral formulation of Wegovy (semaglutide) for chronic weight management in adults living with obesity or overweight with one or more comorbid conditions and to reduce the risk of major adverse cardiovascular events in adults with overweight or obesity and established cardiovascular disease

The duration of your program will depend on the amount of weight you want to lose as well as how effective the drug and your individual lifestyle changes are

Patients receiving compounded versions are extrapolating clinical evidence from STEP-1 (Wegovys pivotal trial), which showed average weight loss of 14.9% over 68 weeks at the 2.4 mg dose

Clinical Development Status Its crucial to understand that triple-agonist medications are not yet FDA-approved

For understanding units, see our guide on how many mg is 20 units of tirzepatide